Furthermore, in clinical studies, TRPV1, TRPA1, and TRPM8 agonists improved the efficacy, safety, and physiology of swallowing in patients with oropharyngeal dysphagia (Ebihara et al., 1993, 2006; Rofes et al., 2013, 2014; Ortega et al., 2016; Shin et al., 2016; Nakato et al., 2017; Alvarez-Berdugo et al., 2018; Tomsen et al., 2019, 2020, 2022; Cheng et al., 2022). The gene discussed is TRPV1; the disease is Oral-pharyngeal dysphagia.